Clinical Trials Logo

Clinical Trial Summary

A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.


Clinical Trial Description

This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination. Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04792684
Study type Observational
Source Universal Diagnostics
Contact Alvaro Leiva
Phone (+34) 674 94 55 33
Email aleiva@universaldx.com
Status Recruiting
Phase
Start date December 30, 2020
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Completed NCT01450319 - A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype Phase 2
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT03253185 - A Study of SC-007 in Subjects With Advanced Cancer Phase 1
Completed NCT00851045 - Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer Phase 2
Recruiting NCT06026410 - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Phase 1
Recruiting NCT04622423 - Advanced Therapies for Liver Metastases
Active, not recruiting NCT02955940 - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Phase 2
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT03314935 - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT05379985 - Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Phase 1
Recruiting NCT05648955 - Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment Early Phase 1
Completed NCT00165854 - Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer Phase 2
Recruiting NCT05706129 - A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02646748 - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Phase 1
Not yet recruiting NCT02005913 - A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence N/A
Recruiting NCT04256707 - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Phase 1/Phase 2
Completed NCT00483080 - Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) Phase 2